Abediterol

Abediterol (INN;^[2] development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed.

Abediterol

Clinical data
Routes of administration	Inhalation
ATC code	None
Pharmacokinetic data
Elimination half-life	24.3 hours[1]
Identifiers
IUPAC name 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number	915133-65-2
PubChem CID	11962616
IUPHAR/BPS	9326
ChemSpider	10136846 Y
UNII	QXA167CM6F
KEGG	D10219 Y
ChEBI	CHEBI:142077
ChEMBL	ChEMBL3039530 Y
CompTox Dashboard (EPA)	DTXSID60238605
Chemical and physical data
Formula	C25H30F2N2O4
Molar mass	460.522 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
InChI InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 Y Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N Y

History

Abediterol was under development by the Spanish pharmaceutical company Almirall and reached Phase II clinical trials,^[3][4] but was discontinued in 2021.^[5] Its coformulation with mometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.^[6]

Mechanism of action

Abediterol is an ultra-long-acting β₂ agonist (ultra-LABA).^[7][8][9]